New drug duo aims to outsmart tough lung cancers
NCT ID NCT04467723
Summary
This study is testing whether adding an oral drug called pirfenidone to an existing immunotherapy (atezolizumab) can help control advanced non-small cell lung cancer that has come back or spread after initial treatments. It will involve about 25 adults to first check safety and then see if the combination can shrink tumors and help patients live longer. The goal is to see if this approach can overcome the cancer's resistance to standard immunotherapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC STAGE IV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Kansas Cancer Center (KUCC)
NOT_YET_RECRUITINGFairway, Kansas, 66205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The University of Kansas Cancer Center, Westwood Campus
RECRUITINGKansas City, Kansas, 66205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.